Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 20/20 | 0.66 |
| ▸ | CDC42BPB | Q9Y5S2 | 20/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 18/20 | 0.66 |
| ▸ | CDC42BPA | Q5VT25 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842497 | 0.83 | ROCK1 (0.75) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL1839716 | 0.83 | ROCK1 (0.75) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL2236999 | 0.82 | ROCK1 (0.73) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672458 | 0.80 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL29869742 | 0.80 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL20744561 | 0.79 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL30668730 | 0.79 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL29869437 | 0.79 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672134 | 0.79 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24673120 | 0.78 | ROCK2 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011526931-A | — | — | 2011-10-20 | — | — | JP | claimed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | claimed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | ROCK1 759/4885CDC42BPB 630/4885ROCK2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.